Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
−Removed: Our common stock trades on The Nasdaq Global Select Market under the symbol “TORC”.
−Removed: Trading of our common stock commenced on January 26, 2018, in connection with our initial public offering, or IPO.
+Added: Our common stock trades on The Nasdaq Global Market under the symbol “ACET”.
+Added: Trading of our common stock commenced on January 26, 2018, in connection with our initial public offering of resTORbio.
Prior to that time, there was no established public trading market for our common stock.
9 unchanged sentences
The information required by Item 5 of Form 10‑K regarding equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report on Form 10‑K.
+Added: Recent Sales of Unregistered Securities
+Added: Securities Purchase Agreement
+Added: On February 12, 2021, we entered into a stock purchase agreement with certain existing investors for $15.0 million of shares of our common stock, with an initial closing for certain investors held simultaneously with the closing of our February 2021 public offering and a subsequent closing for certain additional investors.
+Added: Pursuant to the terms of the private placement, we issued 1,153,840 shares of common stock at a price of $13.00 per share, which was the price per share of our February 2021 public offering.
+Added: We received the full proceeds from the sale and did not pay any underwriting discounts or commissions with respect to the shares of common stock that sold in the concurrent private placement.
+Added: Proceeds from the private placement will be used primarily to fund activities related to our internal discovery research, other pipeline candidates and to fund the continued development of our gamma delta T cell platform;
+Added: the external costs for the development of ADI-001 through the completion of a Phase 1 dose expansion study for ADI-001 in NHL;
+Added: the external costs for the development of ADI-002 through the completion of a Phase 1 dose finding study for ADI-002 in solid tumors;
+Added: and the remainder, if any, to fund working capital and other general corporate purposes.
+Added: The private placement was exempt from registration pursuant to Section 4(a)(2) of the Securities Act as a transaction by an issuer not involving a public offering.
Purchase of Equity Securities by the Issuer and Affiliated Purchasers
We did not purchase any of our equity securities during the period covered by this Annual Report on Form 10-K.
−Removed: Selected Financial Data.
−Removed: Information requested by this Item 6.
−Removed: Selected Financial Data is not applicable as we are electing scaled disclosure requirements available to Smaller Reporting Companies with respect to this Item 6.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.